[2-[2-[1-[[4-[5-[(Ethylamino)carbonyl]-2-methylphenyl]-3,4-dihydro-3-oxopyrazinyl]amino]-1-methylethyl]phenoxy]ethyl]methyl-carbamic acid phenylmethyl ester → N-Ethyl-4-methyl-3-[3-[[1-methyl-1-[2-[2-(methylamino)ethoxy]phenyl]ethyl]amino]-2-oxo-1(2H)-pyrazinyl]-benzamide
反応式
C1(CO[C:9](=O)[N:10]([CH2:12][CH2:13][O:14][C:15]2[CH:20]=[CH:19][CH:18]=[CH:17][C:16]=2[C:21]([NH:24][C:25]2[C:30](=[O:31])[N:29]([C:32]3[CH:37]=[C:36]([C:38]([NH:40][CH2:41][CH3:42])=[O:39])[CH:35]=[CH:34][C:33]=3[CH3:43])[CH:28]=[CH:27][N:26]=2)([CH3:23])[CH3:22])C)C=CC=CC=1>[Pd].C(O)C>[CH2:41]([NH:40][C:38](=[O:39])[C:36]1[CH:35]=[CH:34][C:33]([CH3:43])=[C:32]([N:29]2[CH:28]=[CH:27][N:26]=[C:25]([NH:24][C:21]([CH3:22])([C:16]3[CH:17]=[CH:18][CH:19]=[CH:20][C:15]=3[O:14][CH2:13][CH2:12][NH:10][CH3:9])[CH3:23])[C:30]2=[O:31])[CH:37]=1)[CH3:42]参加物
4
反応物 1
生成物 1
試薬・触媒・溶媒 2
実験手順
To [2-[2-[1-[[4-[5-[(ethylamino)carbonyl]-2-methylphenyl]-3,4-dihydro-3-oxopyrazinyl]amino]-1-methylethyl]phenoxy]ethyl]methyl-carbamic acid phenylmethyl ester (Example 220d, 1.10 g) was added ethanol (10 mL) and this was pumped through a Pd/C cartridge at 1 mL/min under max H2 at 50° C. on an H-Cube hydrogenator. The solvents were removed in vacuo and the residue then taken up in acetonitrile. Purification by preparative HPLC (ACE column, 0.2% TFA:acetonitrile eluent) followed by treatment with SCX resin (eluting with methanol (discarded) followed by 7N NH3 in methanol and collected the basic fractions) and trituration with diethyl ether afforded the title product (2 mg).
後処理
- customThe solvents were removed in vacuo
- customPurification by preparative HPLC (ACE column, 0.2% TFA:acetonitrile eluent)
- washeluting with methanol (discarded)
- customcollected the basic fractions) and trituration with diethyl ether
出典と根拠
- ORDレコード
- ord-568725e1f91640d2bf3499a16b966fe2
- 出典データセット
- uspto-grants-2012_04
- 特許番号
- US08163905B2
反応ノート
読み込み中…